Shanghai Henlius Biotech (HKG:2696) dosed the first patient in an international multi-center phase 1 study of a HLX17 in the United States, according to a Friday Hong Kong bourse filing.
The trial is studying the drug in patients with multiple resected solid tumors.
A phase 1 trial of the drug is simultaneously being conducted in Mainland China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments